BRCA1 and ovarian cancer: Additional work then demonstrated that, similar to breast and ovarian cancers harboring BRCA1/2 mutations, Ewing’s sarcomas may also have defects in DNA repair mechanisms, rendering them sensitive to PARP inhibition (Stewart et al., 2014).